Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Liabilities (2023 - 2025)

Immunome (IMNM) has disclosed Total Liabilities for 3 consecutive years, with $48.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 17.32% year-over-year to $48.8 million, compared with a TTM value of $48.8 million through Dec 2025, down 17.32%, and an annual FY2025 reading of $48.8 million, down 17.32% over the prior year.
  • Total Liabilities was $48.8 million for Q4 2025 at Immunome, up from $35.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $87.1 million in Q3 2023 and bottomed at $27.0 million in Q2 2025.
  • Average Total Liabilities over 3 years is $42.2 million, with a median of $35.5 million recorded in 2025.
  • Peak annual rise in Total Liabilities hit 106.14% in 2024, while the deepest fall reached 51.78% in 2024.
  • Year by year, Total Liabilities stood at $28.7 million in 2023, then soared by 106.14% to $59.1 million in 2024, then decreased by 17.32% to $48.8 million in 2025.
  • Business Quant data shows Total Liabilities for IMNM at $48.8 million in Q4 2025, $35.5 million in Q3 2025, and $27.0 million in Q2 2025.